Therapeutic effects of hepatocyte transplantation on hemophilia B

Transplantation

Volumn 86, Issue 1, 2008, Pages 167-170

  Tatsumi, Kohei ^a   Ohashi, Kazuo ^a,b   Shima, Midori ^a   Nakajima, Yoshiyuki ^a   Okano, Teruo ^b   Yoshioka, Akira ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Coagulation factor IX; Experimental transplantation; Hemophilia B; Hepatocyte transplantation

Indexed keywords

BLOOD CLOTTING FACTOR 9; MESSENGER RNA; ANTIBODY;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CELL ISOLATION; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; HEMOPHILIA B; HEPATOCYTE TRANSPLANTATION; KNOCKOUT MOUSE; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECIPIENT; THERAPY EFFECT; ANIMAL; BLOOD; BLOOD CLOTTING; C57BL MOUSE; DISEASE MODEL; FEASIBILITY STUDY; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; TIME; TRANSPLANTATION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; FACTOR IX; FEASIBILITY STUDIES; HEMOPHILIA B; HEPATOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME;

EID: 47749106129     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817b9160     Document Type: Article

References (26)

1. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801.
2. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535.
3. Nathwani AC, Davidoff AM, Tuddenham EG. Prospects for gene therapy of haemophilia. Haemophilia 2004; 10: 309.
4. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963.
5. Manno CS, Pierce GF, Arruda VR,et al. Successful transductionof liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342.
6. Gordon FH, Mistry PK, Sabin CA, et al. Outcome of orthotopic liver Transplantation in patients with haemophilia. Gut 1998; 42: 744.
7. Ko S, Tanaka I, Kanehiro H, et al. Preclinical experiment of auxiliary partial orthotopic liver transplantation as a curative treatment for hemophilia. Liver Transpl 2005; 11: 579.
8. Merion RM, Delius RE, Campbell DA, Jr, et al. Orthotopic liver transplantation totally corrects factor IXdeficiency in hemophilia B.Surgery 1988; 104: 929.
9. Boost KA, Auth MK, Woitaschek D, et al. Long-term production of major coagulation factors and inhibitors by primary human hepatocytes in vitro: perspectives for clinical application. Liver Int 2007; 27: 832.
10. Fisher RA, Strom SC. Human hepatocyte transplantation: Worldwide results. Transplantation 2006; 82: 441.
11. Ohashi K, Park F, Kay MA. Hepatocyte transplantation: Clinical and experimental application. J Mol Med 2001; 79: 617.
12. DhawanA,Mitry RR, Hughes RD,etal. Hepatocyte transplantation for inherited factor VII deficiency. Transplantation 2004; 78: 1812.
13. Ohashi K, Waugh JM, Dake MD, et al. Liver tissue engineering at ex-trahepatic sites in mice as a potential new therapy for genetic liver diseases. Hepatology 2005; 41: 132.
14. Berry MN, Friend DS. High-yield preparation of isolated rat liver pa-renchymal cells: A biochemical and fine structural study. J Cell Biol 1969; 43: 506.
15. Ohashi K, Kay MA, Kuge H, et al. Heterotopically transplanted hepa-tocyte survival depends on extracellular matrix components. Transplant Proc 2005; 37: 4587.
16. OhashiK,Kay MA, Yokoyama T,etal. Stability and repeat regeneration potential of the engineered liver tissues under the kidney capsule in mice. Cell Transplant 2005; 14: 621.
17. Lin HF, Maeda N, Smithies O, et al. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997; 90: 3962.
18. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999; 5: 64.
19. Schneider A, Attaran M, Gratz KF, et al. Intraportal infusion of 99mtechnetium-macro-aggregrated albumin particles and hepatocytes in rabbits: Assessment of shunting and portal hemodynamic changes. Transplantation 2003; 75: 296.
20. Kasper CK, Pool JG. Letter: Measurementof mild factor VIII inhibitors in Bethesda units. Thromb Diath Haemorrh 1975; 34: 875.
21. Arruda VR, Hagstrom JN, Deitch J, et al. Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood 2001; 97: 130.
22. Kokudo N, Ohashi K, Takahashi S, et al. Effect of 70% hepatectomy on DNA synthesis in rat hepatocyte isograft into the spleen. Transplant Proc 1994; 26: 3464.
23. Zhang H, Miescher-Clemens E, Drugas G, et al. Intrahepatic hepato-cyte transplantation following subtotal hepatectomy in the recipient: A possible model in the treatment of hepatic enzyme deficiency. J Pediatr Surg 1992; 27: 312.
24. Ohashi K, Marion PL, Nakai H, et al. Sustained survival of human hepatocytesin mice:Amodel forinvivo infection with human hepatitis B and hepatitis delta viruses. Nat Med 2000; 6: 327.
25. Yokoyama T, Ohashi K, Kuge H, et al. In vivo engineering of metabol-ically active hepatic tissues in a neovascularized subcutaneous cavity. Am J Transplant 2006; 6: 50.
26. Ohashi K, Yokoyama T, Yamato M, et al. Engineering functional two-and three-dimensional liver systems in vivo using hepatic tissue sheets. Nat Med 2007; 13: 880.